{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T22:20:36Z","timestamp":1788733236774,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-99773-4","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T10:35:45Z","timestamp":1745922945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Gastrointestinal adverse events associated with Lenvatinib versus Lenvatinib plus Pembrolizumab: A pharmacovigilance study in FDA adverse event reporting system"],"prefix":"10.1038","volume":"15","author":[{"given":"Chufeng","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yankun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenpo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qimin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"99773_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2015","unstructured":"Haugen, B. R. et al. American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1\u2013133. https:\/\/doi.org\/10.1089\/thy.2015.0020 (2015).","journal-title":"Thyroid"},{"key":"99773_CR2","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva, A. Hepatocellular carcinoma. N. Engl. J. Med. 380, 1450\u20131462. https:\/\/doi.org\/10.1056\/NEJMra1713263 (2019).","journal-title":"N. Engl. J. Med."},{"key":"99773_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.9","author":"JJ Hsieh","year":"2017","unstructured":"Hsieh, J. J. et al. Renal cell carcinoma. Nat. Rev. Dis. Prim. https:\/\/doi.org\/10.1038\/nrdp.2017.9 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"13","key":"99773_CR4","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.3390\/jcm11133912","volume":"11","author":"A Rizzo","year":"2022","unstructured":"Rizzo, A. Immune Checkpoint Inhibitors and Mismatch Repair Status in Advanced Endometrial Cancer: Elective Affinities. J. Clin. Med. 11(13), 3912. https:\/\/doi.org\/10.3390\/jcm11133912 (2022).","journal-title":"J. Clin. Med."},{"key":"99773_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1079716","author":"Y Matsuura","year":"2022","unstructured":"Matsuura, Y. et al. Case report: Posterior reversible encephalopathy syndrome, an adverse effect of lenvatinib and pembrolizumab combination therapy, in a patient with advanced endometrial cancer. Front. Oncol. https:\/\/doi.org\/10.3389\/fonc.2022.1079716 (2022).","journal-title":"Front. Oncol."},{"key":"99773_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/17425255.2018.1461839","volume":"14","author":"S Cavalieri","year":"2018","unstructured":"Cavalieri, S. et al. Lenvatinib-induced renal failure: Two first-time case reports and review of literature. Expert Opin. Drug Met. 14, 379\u2013385. https:\/\/doi.org\/10.1080\/17425255.2018.1461839 (2018).","journal-title":"Expert Opin. Drug Met."},{"key":"99773_CR7","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.2169\/internalmedicine.7300-21","volume":"61","author":"T Imakura","year":"2022","unstructured":"Imakura, T. et al. Lenvatinib-induced interstitial pneumonia in a patient with hepatocellular carcinoma. Intern. Med. 61, 1211\u20131217. https:\/\/doi.org\/10.2169\/internalmedicine.7300-21 (2022).","journal-title":"Intern. Med."},{"issue":"6","key":"99773_CR8","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1177\/10781552231178461","volume":"29","author":"C Eisinger","year":"2023","unstructured":"Eisinger, C. & Muluneh, B. Combined use of pembrolizumab and lenvatinib: A review. J. Oncol. Pharm. Pract. 29(6), 1461\u20131466. https:\/\/doi.org\/10.1177\/10781552231178461 (2023).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"99773_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2023.2219390","author":"H Yang","year":"2023","unstructured":"Yang, H. et al. A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database. Expert Opin. Drug Met. https:\/\/doi.org\/10.1080\/17425255.2023.2219390 (2023).","journal-title":"Expert Opin. Drug Met."},{"key":"99773_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1169735","author":"Y Shu","year":"2023","unstructured":"Shu, Y., Chen, J., Ding, Y. & Zhang, Q. Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1169735 (2023).","journal-title":"Front. Immunol."},{"key":"99773_CR11","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1111\/bcp.14868","volume":"87","author":"R Bohm","year":"2021","unstructured":"Bohm, R. et al. Pharmacovigilance-based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections. Br. J. Clin. Pharmacol. 87, 4421\u20134431. https:\/\/doi.org\/10.1111\/bcp.14868 (2021).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"99773_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071752","author":"MM Dhodapkar","year":"2022","unstructured":"Dhodapkar, M. M. et al. Characterization and corroboration of safety signals identified from the US food and drug administration adverse event reporting system, 2008\u201319: Cross sectional study. BMJ https:\/\/doi.org\/10.1136\/bmj-2022-071752 (2022).","journal-title":"BMJ"},{"key":"99773_CR13","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda, T., Tamon, A., Kadoyama, K. & Okuno, Y. Data mining of the public version of the FDA adverse event reporting system. Int. J. Med. Sci. 10, 796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048 (2013).","journal-title":"Int. J. Med. Sci."},{"key":"99773_CR14","doi-asserted-by":"publisher","first-page":"e28671","DOI":"10.1002\/jmv.28671","volume":"95","author":"A Sharma","year":"2023","unstructured":"Sharma, A., Roy, S., Sharma, R. & Kumar, A. Association of antiviral drugs and their possible mechanisms with DRESS syndrome using data mining algorithms. J. Med. Virol. 95, e28671. https:\/\/doi.org\/10.1002\/jmv.28671 (2023).","journal-title":"J. Med. Virol."},{"key":"99773_CR15","unstructured":"Food and Drug Administration, HHS.\u00a0International Conference on Harmonisation; Electronic Transmission of Postmarket Individual Case Safety Reports for Drugs and Biologics,\u00a0Excluding Vaccines; Availability of Food and Drug Administration Regional Implementation Specifications for ICH E2B(R3) Reporting to the Food and Drug Administration Adverse Event Reporting System. Notice of availability.Fed Regist. 81(121):40890\u201340891. (2016)"},{"issue":"4","key":"99773_CR16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40264-015-0388-3","volume":"39","author":"S Seabroke","year":"2016","unstructured":"Seabroke, S. et al. Performance of stratified and subgrouped disproportionality analyses in spontaneous databases. Drug Saf. 39(4), 355\u2013364. https:\/\/doi.org\/10.1007\/s40264-015-0388-3 (2016).","journal-title":"Drug Saf."},{"issue":"1","key":"99773_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2013","unstructured":"Nor\u00e9n, G. N., Hopstadius, J. & Bate, A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat. Methods Med. Res. 22(1), 57\u201369. https:\/\/doi.org\/10.1177\/0962280211403604 (2013).","journal-title":"Stat. Methods Med. Res."},{"key":"99773_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2312","author":"J Zhou","year":"2023","unstructured":"Zhou, J. et al. Disproportionality analysis of lenvatinib-caused gastrointestinal perforation in cancer patients: A pharmacovigilance based on the Food and drug administration adverse event reporting system. J. Clin. Pharmacol. https:\/\/doi.org\/10.1002\/jcph.2312 (2023).","journal-title":"J. Clin. Pharmacol."},{"key":"99773_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1160117","author":"Y Xue","year":"2023","unstructured":"Xue, Y., Feng, S., Li, G. & Zhang, C. Safety profile of vascular endothelial growth factor receptor tyrosine-kinase inhibitors in pediatrics: A pharmacovigilance disproportionality analysis. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2023.1160117 (2023).","journal-title":"Front. Pharmacol."},{"key":"99773_CR20","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1177\/1078155218817109","volume":"25","author":"C Cheng","year":"2019","unstructured":"Cheng, C., Nayernama, A., Christopher, J. S., Casey, D. & Waldron, P. E. Wound healing complications with lenvatinib identified in a pharmacovigilance database. J. Oncol. Pharm. Pract. 25, 1817\u20131822. https:\/\/doi.org\/10.1177\/1078155218817109 (2019).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"99773_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1209933","author":"X Wang","year":"2023","unstructured":"Wang, X., Yin, D., Tang, Y., Xiao, F. & Wang, S. Psychiatric adverse reactions to non-selective RET multi-kinase inhibitors: A large-scale pharmacovigilance analysis. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2023.1209933 (2023).","journal-title":"Front. Pharmacol."},{"issue":"5","key":"99773_CR22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1159\/000514182","volume":"10","author":"L Valerio","year":"2021","unstructured":"Valerio, L. et al. Prevalence and risk factors of developing fistula or organ perforation in patients treated with lenvatinib for radioiodine-refractory thyroid cancer. Eur. Thyroid. J. 10(5), 399\u2013407. https:\/\/doi.org\/10.1159\/000514182 (2021).","journal-title":"Eur. Thyroid. J."},{"issue":"13","key":"99773_CR23","doi-asserted-by":"publisher","first-page":"e37606","DOI":"10.1097\/MD.0000000000037606","volume":"103","author":"A Di Marco","year":"2024","unstructured":"Di Marco, A., Artioli, G., Favaretto, A., Cavasin, N. & Basso, U. Multiorgan failure caused by pembrolizumab and axitinib in a woman affected by metastatic clear cell renal cell carcinoma: A case report and literature review. Med. (Baltimore) 103(13), e37606. https:\/\/doi.org\/10.1097\/MD.0000000000037606 (2024).","journal-title":"Med. (Baltimore)"},{"key":"99773_CR24","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/S1470-2045(21)00387-9","volume":"22","author":"N Gaspar","year":"2021","unstructured":"Gaspar, N. et al. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): A multicentre, open-label, multicohort, phase 1\/2 study. Lancet Oncol. 22, 1312\u20131321. https:\/\/doi.org\/10.1016\/S1470-2045(21)00387-9 (2021).","journal-title":"Lancet Oncol."},{"key":"99773_CR25","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/bjc.2012.154","volume":"106","author":"DS Boss","year":"2012","unstructured":"Boss, D. S. et al. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Brit. J. Cancer. 106, 1598\u20131604. https:\/\/doi.org\/10.1038\/bjc.2012.154 (2012).","journal-title":"Brit. J. Cancer."},{"key":"99773_CR26","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1200\/JCO.20.03093","volume":"39","author":"LJ Wirth","year":"2021","unstructured":"Wirth, L. J. et al. Open-label, single-arm, multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer. J. Clin. Oncol. 39, 2359\u20132366. https:\/\/doi.org\/10.1200\/JCO.20.03093 (2021).","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"99773_CR27","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1016\/j.cgh.2018.06.042","volume":"17","author":"MP da Costa","year":"2019","unstructured":"da Costa, M. P., Lu\u00eds, R. & Lopes, J. Hepatocellular carcinoma invading the gastric antrum. Clin. Gastroenterol. Hepatol. 17(9), e102\u2013e103. https:\/\/doi.org\/10.1016\/j.cgh.2018.06.042 (2019).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"42","key":"99773_CR28","doi-asserted-by":"publisher","first-page":"7472","DOI":"10.3748\/wjg.v19.i42.7472","volume":"19","author":"H Sayana","year":"2013","unstructured":"Sayana, H., Yousef, O. & Clarkston, W. K. Massive upper gastrointestinal hemorrhage due to invasive hepatocellular carcinoma and hepato-gastric fistula. World J. Gastroenterol. 19(42), 7472\u20137475. https:\/\/doi.org\/10.3748\/wjg.v19.i42.7472 (2013).","journal-title":"World J. Gastroenterol."},{"issue":"24","key":"99773_CR29","doi-asserted-by":"publisher","first-page":"02345","DOI":"10.1016\/j.eururo.2024.05.003","volume":"S0302\u20132838","author":"CH Lee","year":"2024","unstructured":"Lee, C. H. et al. Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111\/KEYNOTE-146. Eur. Urol. S0302\u20132838(24), 02345\u201302355. https:\/\/doi.org\/10.1016\/j.eururo.2024.05.003 (2024).","journal-title":"Eur. Urol."},{"issue":"9","key":"99773_CR30","doi-asserted-by":"publisher","first-page":"e30257","DOI":"10.1016\/j.heliyon.2024.e30257","volume":"10","author":"W Sultan","year":"2024","unstructured":"Sultan, W. et al. The efficacy and safety of the novel combination lenvatinib and pembrolizumab in endometrial cancer: A systematic review and single-arm meta-analysis. Heliyon. 10(9), e30257. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30257 (2024).","journal-title":"Heliyon."},{"issue":"2","key":"99773_CR31","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2174\/157488408784293705","volume":"3","author":"JM Roodhart","year":"2008","unstructured":"Roodhart, J. M., Langenberg, M. H., Witteveen, E. & Voest, E. E. The molecular basis of class side effects due to treatment with inhibitors of the VEGF\/VEGFR pathway. Curr. Clin. Pharmacol. 3(2), 132\u2013143. https:\/\/doi.org\/10.2174\/157488408784293705 (2008).","journal-title":"Curr. Clin. Pharmacol."},{"issue":"1","key":"99773_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11864-007-0022-4","volume":"8","author":"E Cabebe","year":"2007","unstructured":"Cabebe, E. & Wakelee, H. Role of anti-angiogenesis agents in treating NSCLC: Focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr. Treat. Options Oncol. 8(1), 15\u201327. https:\/\/doi.org\/10.1007\/s11864-007-0022-4 (2007).","journal-title":"Curr. Treat. Options Oncol."},{"issue":"6","key":"99773_CR33","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","volume":"10","author":"S Hapani","year":"2009","unstructured":"Hapani, S., Chu, D. & Wu, S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: A meta-analysis. Lancet Oncol. 10(6), 559\u2013568. https:\/\/doi.org\/10.1016\/S1470-2045(09)70112-3 (2009).","journal-title":"Lancet Oncol."},{"issue":"10","key":"99773_CR34","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/apt.16601","volume":"54","author":"TA Wichelmann","year":"2021","unstructured":"Wichelmann, T. A., Abdulmujeeb, S. & Ehrenpreis, E. D. Bevacizumab and gastrointestinal perforations: A review from the FDA Adverse Event Reporting System (FAERS) database. Aliment. Pharmacol. Ther. 54(10), 1290\u20131297. https:\/\/doi.org\/10.1111\/apt.16601 (2021).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"2","key":"99773_CR35","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s13691-024-00657-7","volume":"13","author":"M Kurokawa","year":"2024","unstructured":"Kurokawa, M. et al. A case of postoperative pancreatitis in patients with renal cell carcinoma with an inferior vena cava tumor thrombus treated by presurgical lenvatinib plus pembrolizumab. Int. Cancer Conf. J. 13(2), 158\u2013161. https:\/\/doi.org\/10.1007\/s13691-024-00657-7 (2024).","journal-title":"Int. Cancer Conf. J."},{"issue":"12","key":"99773_CR36","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","volume":"24","author":"JM Llovet","year":"2023","unstructured":"Llovet, J. M. et al. LEAP-002 Investigators. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): A randomised, double-blind, phase 3 trial. Lancet Oncol. 24(12), 1399\u20131410. https:\/\/doi.org\/10.1016\/S1470-2045(23)00469-2 (2023).","journal-title":"Lancet Oncol."},{"issue":"186","key":"99773_CR37","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ygyno.2024.04.011","volume":"7","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2024","unstructured":"Gonz\u00e1lez-Mart\u00edn, A. et al. Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study. Gynecol Oncol. 7(186), 182\u2013190. https:\/\/doi.org\/10.1016\/j.ygyno.2024.04.011 (2024).","journal-title":"Gynecol Oncol."},{"issue":"10126","key":"99773_CR38","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet 391(10126), 1163\u20131173 (2018).","journal-title":"Lancet"},{"issue":"5","key":"99773_CR39","first-page":"678","volume":"6","author":"F Conforti","year":"2020","unstructured":"Conforti, F. et al. Sex-based differences in response to anti-PD-1\/PD-L1 therapy: A systematic review and meta-analysis. JAMA Oncol. 6(5), 678\u2013681 (2020).","journal-title":"JAMA Oncol."},{"issue":"26","key":"99773_CR40","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. J. Clin. Oncol. 38(26), 2960\u20132970 (2020).","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"99773_CR41","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.3390\/ijms25073933","volume":"25","author":"A Maltseva","year":"2024","unstructured":"Maltseva, A. et al. Predicting Response to Immunotargeted Therapy in Endometrial Cancer via Tumor Immune Microenvironment: A Multicenter, Observational Study. Int. J. Mol. Sci. 25(7), 3933. https:\/\/doi.org\/10.3390\/ijms25073933 (2024).","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"99773_CR42","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s12072-022-10480-y","volume":"17","author":"X Yang","year":"2023","unstructured":"Yang, X. et al. Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients. Hepatol. Int. 17(3), 709\u2013719. https:\/\/doi.org\/10.1007\/s12072-022-10480-y (2023).","journal-title":"Hepatol. Int."},{"issue":"4","key":"99773_CR43","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/14737140.2022.2039123","volume":"22","author":"RJ Motzer","year":"2022","unstructured":"Motzer, R. J. et al. Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies. Expert Rev. Anticancer Ther. 22(4), 383\u2013400 (2022).","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"10","key":"99773_CR44","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","volume":"15","author":"JM Llovet","year":"2018","unstructured":"Llovet, J. M. et al. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 15(10), 599\u2013616 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"99773_CR45","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","volume":"28","author":"N Chaput","year":"2017","unstructured":"Chaput, N. et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann. Oncol. 28(6), 1368\u20131379 (2017).","journal-title":"Ann. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99773-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99773-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99773-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T10:35:53Z","timestamp":1745922953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99773-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["99773"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-99773-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"26 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15047"}}